“…There was a good number of CE investigations of pharmaceuticals/herbal product compounds 138, 150–153, 157, 159, 166–169, 171, 172, 176, 178–180, 182, 186, 187, 341, 357–375 during this review period. Mostly performed in MEKC mode, these included the determination of biogenic amines (toxicological‐risk agents) 364, toxic pyrrolizidine alkaloids in G ynura segenum (a health‐risk plant species) 168, diterpenoids in Salvia species (a herbal remedy and food flavor) 166, statins (cholesterol‐lowering drugs, some of which are naturally occurring) 365 in drug products.…”